
|Articles|March 8, 2010
- September 2009
- Volume 3
- Issue 9
IASLC's 13th World Conference on Lung Cancer
Author(s)Onclive Team
Key Takeaways
- Personalized treatment strategies have advanced the management of lung cancer brain metastases, improving patient outcomes.
- Targeted therapies and immunotherapies offer more effective, less invasive options compared to traditional methods.
Advertisement
Articles in this issue
almost 16 years ago
Abraxis BioScience Hopes to 'Nab' a Bigger Share of the Taxanes Marketalmost 16 years ago
Studies from Around the Globealmost 16 years ago
By the Numbers: If the US Health Care System Had Only 100 Physiciansalmost 16 years ago
In the News BriefsAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
5



































